Invex Therapeutics Ltd (ASX: IXC) - Share Price
- Current share price for IXC : $0.100
Invex Therapeutics Ltd (IXC) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is a biopharmaceutical company focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure. Invex has trademarked its repurposed Exenatide as Presendin.
IXC General Information +
| ASX Code | IXC |
| Website | http://www.invextherapeutics.com |
| Industry/Sector | Pharmaceuticals |
| Market Cap ($M) | 7 |
| IXC Share Price | $0.100 |
| Day High | $0.000 |
| Day Low | $0.000 |
| Last Close | $0.100 |
| IXC Share Price Movement | - ( No change ) |
Prices as at 16:40, 30 Oct 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Invex Therapeutics Ltd (IXC) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|
See all dividends from Invex Therapeutics Ltd (IXC) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Invex Therapeutics Ltd (IXC) price-sensitive announcements
IXC - Quarterly Activities/Appendix 4C Cash Flow Report
Invex Therapeutics Ltd’s September 2026 quarterly activities report and Appendix 4C for Q1
Invex Therapeutics Ltd (IXC)
30 Oct 2026 | 12:06 PM
30 Oct 2026 | 12:06 PM
IXC - Invex to Acquire Rekover Therapeutics
Invex Therapeutics Limited announced it has entered a binding share sale and purchase agre
Invex Therapeutics Ltd (IXC)
26 Oct 2026 | 9:42 AM
26 Oct 2026 | 9:42 AM
IXC - Trading Halt
ASX announced that trading in Invex Therapeutics Limited (ASX: IXC) securities was placed
Invex Therapeutics Ltd (IXC)
22 Oct 2026 | 9:20 AM
22 Oct 2026 | 9:20 AM
IXC - Appendix 4E and Annual Report to shareholders
Invex Therapeutics Ltd’s Appendix 4E and 2026 Annual Report for the Australian financial y
Invex Therapeutics Ltd (IXC)
31 Aug 2026 | 7:17 PM
31 Aug 2026 | 7:17 PM
Invex Therapeutics Ltd (IXC) Recent ASX Announcements
IXC Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2026A | -$1.35 | -$1.80 | 185.70% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2025A | -$0.48 | -$0.60 | -71.10% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$1.64 | -$2.20 | -78.90% | 0.00 | 0.00 | 0.00% | 0.0% |
IXC Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2024 A | 2025 A | 2026 A | 2024 A | 2025 A | 2026 A | 2024 A | 2025 A | 2026 A | ||
| Clarity Pharmaceuticals Ltd (CU6) | $623M | 0.4454 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Invex Therapeutics Ltd (IXC) | $8M | 1.8571 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Neuren Pharmaceuticals Limited (NEU) | $2,553M | -0.7857 | 0.2462 | 0.9655 | 86.5492 | 69.4483 | 35.3333 | 0.00% | 1.64% | 1.94% |
IXC Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.00 | 0.00 | 1.92 | 0.00 |
| Market | 0.30 | 13.20 | 1.03 | 0.74 |
| Sector | 0.78 | 36.70 | 2.28 | 2.18 |
IXC Directors
| Name | Position | Start Date |
|---|---|---|
| Mr David Colin Wheeler | Non-Executive Chairman, Non-Executive Director | 8 Nov 2023 |
| Mr Simon Llewellyn Owen | Non-Executive Director | 10 Nov 2025 |
| Professor Warren John Harding | Non-Executive Director | 10 Nov 2025 |
Invex Therapeutics Ltd (IXC) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 27 Mar 2024 | DUTHY, Thomas (Tom) | Transfer | Indirect Shares | 285,661 | $0.075 | $21,424.580 |
| 27 Mar 2024 | DUTHY, Thomas (Tom) | Transfer | Indirect Shares | 285,661 | $0.075 | $21,424.580 |
| 24 Aug 2023 | DUTHY, Thomas (Tom) | Buy | Indirect Shares | 178,738 | $0.180 | $32,172.840 |
See all changes in directors' interest & trades for Invex Therapeutics Ltd (IXC) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
IXC Management
| Name | Position |
|---|---|
| Timothy (Tim) Ryan Slate | Company Secretary |
IXC Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Invex Therapeutics Ltd (IXC). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 8,846,154 (11.77%) | Tattarang Pty Ltd |
| 4,450,000 (5.92%) | CELTIC CAPITAL PTE LTD <INVESTMENT 1 A/C> |
IXC Calendar of Events
| Date | Event |
|---|---|
| 30 August 2027 | Report (Annual) |
| 30 August 2027 | Report (Prelim) |
| 11 February 2027 | Report (Interim) |
| 20 November 2026 | AGM |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
